Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 959 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Escalation Clear all

Conditions: Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
Interventions: Descartes-08; Drug
Lead sponsor: Cartesian Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • Cincinnati, Ohio

Conditions: Intraoperative Ureter Injury
Interventions: Nerindocianine for Injection; Drug
Lead sponsor: Li-Cor, Inc.; Industry
Eligibility: 19 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Interventions: RO7566802, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more

Conditions: Advanced Renal Cell Carcinoma, Advanced Melanoma
Interventions: Sitagliptin, Pembrolizumab; Drug
Lead sponsor: Fernando Maciel Barbosa; Other
Eligibility: 18 Years to 99 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Interventions: JCAR017, Lymphodepleting, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Celgene; Industry
Eligibility: Up to 25 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 9
States / cities: Duarte, California • Redwood City, California • St. Petersburg, Florida + 6 more

Conditions: Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Double-hit Lymphoma (DHL), Triple-hit Lymphoma (THL), Double-expressor Lymphoma (DEL), High-grade B-cell Lymphoma (HGBL)
Interventions: fimepinostat, Rituximab, venetoclax; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 11
States / cities: Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 8 more

Conditions: Uterine Cancer
Interventions: Imatinib Mesylate, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oropharyngeal Neoplasms
Interventions: Intensity-modulated radiation therapy (IMRT), Cisplatin; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Scottsdale, Arizona • St Louis, Missouri

Conditions: Clear Cell Renal Carcinoma
Interventions: MK-3475, Bevacizumab; Drug
Lead sponsor: Arkadiusz Z. Dudek, MD; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 5 more

Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Interventions: Emavusertib, Ibrutinib; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more

Conditions: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
Interventions: Phase 1b: APG-115+pembrolizumab; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 14 more

Conditions: Healthy
Interventions: SPY002-091, Placebo; Drug · Other
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic Syndrome Acute Myeloid Leukemia
Interventions: Nivolumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Refractory Solid Tumors
Interventions: Eribulin, Irinotecan, Temozolomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 25 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed and/or Refractory B-cell Lymphoma
Interventions: Cyclophosphamide, Fludarabine, KITE-363, KITE-753; Drug · Biological
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 21
States / cities: Gilbert, Arizona • Duarte, California • Stanford, California + 17 more

Conditions: Metastatic Prostate Cancer
Interventions: AZD0516, AZD9574; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more

Conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: Glofitamab, Obinutuzumab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 6
States / cities: Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more

Conditions: Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung, Colorectal Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions: AVA6103; Drug
Lead sponsor: Avacta Life Sciences Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more

Conditions: Human Immunodeficiency Virus
Interventions: TMB-607, Placebo; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer, Neoplasm, Tumor, Lymphoma, Malignant, Lymphoma, B-cell, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, Chronic, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Chronic, B Cell, Myelofibrosis, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, Lymphoma, T Cell, Peripheral, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Peripheral
Interventions: ASN002 Dose Escalation, ASN002 RD; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Tempe, Arizona • San Francisco, California • Atlanta, Georgia + 9 more

Conditions: Breast Cancer
Interventions: XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Fort Meyers, Florida + 8 more

Conditions: Multiple Sclerosis, Myasthenia Gravis
Interventions: CC-97540, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more

Conditions: Type 2 Diabetes Mellitus
Interventions: SAR425899; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas

Search by objective public record fields.

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Sitagliptin With Pembro in RCC and Melanoma

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

A Study of SPY002-091 in Healthy Volunteers

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period